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Chronic rhinosinusitis (CRS), bronchial asthma and COPD are
chronic inﬂammatory diseases of the respiratory tract, and the ma-
jor causes of acute exacerbations of these airway diseases are viral
infections.1,2 Viral infection induces the expression of a variety of
proinﬂammatory molecules in the airway epithelium, which pro-
motes inﬂammatory cell recruitment and activation.3 Chronic in-
ﬂammatory diseases of the upper and lower respiratory tracts
often coexist in the same patients and suggest the ‘united airways’
concept.1 Appropriate anti-inﬂammatory treatment of both the up-
per and lower airways is necessary to control them.1,2
Combinationsof an inhaled corticosteroid (ICS) and longactingb2
agonist (LABA) are used to treat asthma and COPD, and reduce their
acute exacerbations. Actually, combinations of an ICS and LABA syn-
ergistically suppress proinﬂammatory molecules produced by hu-
man rhinovirus-infected or polyinosinic-polycytidylic acid (Poly
[I:C])-stimulated bronchial epithelial cells4,5; however, the inﬂuence
of these drugs on nasal epithelial cells has not been examined.
CCL3, also called macrophage inﬂammatory protein-1a (MIP-
1a), is a proinﬂammatory molecule produced in the airway by viral
infections.6 Bronchial epithelial cells produce CCL3 as a result of viral
infections, and blockade of the CCL3 proinﬂammatory signaling
cascade signiﬁcantly reduces virus-induced lung inﬂammation.6,7
Poly(I:C) mimics the effects of dsRNA intermediates produced in
virus-infected cells.Weﬁrst investigatedmRNAexpression andpro-
tein production of CCL3 in HNEpC after Poly(I:C) stimulation
(Supplementary Methods). HNEpC were stimulated with Poly(I:C)
(1 mg/mL) for 24h, andweobservedmarked increases inmRNAafter
exposure to Poly(I:C) (Fig.1a).We also found that Poly(I:C) increased
the secreted protein levels of CCL3 (P < 0.01) (Fig. 1b).
Since normal human bronchial epithelial cells (NHBE) are
known to have functional ADRB2,8 we next examined whether
functional ADRB2 was expressed on HNEpC. We observed the
strongest mRNA expression in lung tissue in various human tissues
(Supplementary Fig. 1) and found that ADRB2 mRNA was as highly
expressed in HNEpC as in NHBE (Fig. 1c). It is well known that
ADRB2 stimulation results in an increase of intracellular cAMP.9
Thus, we next investigated whether ADRB2 on HNEpCwas involved
in an increase in cAMP. We stimulated HNEpC with the ADRB2-
speciﬁc agonist salmeterol or formoterol for 10 min and conﬁrmed
increased intracellular cAMP levels (Fig. 1d and e). Pretreatment
with the ADRB2-speciﬁc antagonist ICI118,551 (5 mM) inhibited
the increase of intracellular cAMP (Fig. 1d and e).Peer review under responsibility of Japanese Society of Allergology.
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moterol on the Poly(I:C)-induced CCL3 mRNA expression and CCL3
production levels in HNEpC. Both salmeterol and formoterol sup-
pressed the CCL3 mRNA expression (Supplementary Fig. 2a and b)
and levels of CCL3 protein production (Supplementary Fig. 2c and d).
The ADRB2-speciﬁc antagonist ICI118,551 (5 mM) inhibited those sup-
pressive effects of both agonists at the mRNA level (Supplementary
Fig. 2a and b). The antagonist signiﬁcantly inhibited the suppressive
effect of formoterol onprotein expression levels in all of the examined
cell lines (P < 0.01) (Supplementary Fig. 2d). However, the antagonist
signiﬁcantly inhibited the suppressive effect of salmeterol in only
three of the four examined cell lines (Supplementary Fig. 2c).
We next assessed the effects of dexamethasone and the LABAs
salmeterol and formoterol on the induction of CCL3 by Poly(I:C).
The CCL3 mRNA expression was decreased by dexamethasone
and/or a LABA (Fig. 2a and b), and synergistic suppression of CCL3
by dexamethasone and salmeterol (Fig. 2a) or formoterol (Fig. 2b)
was observed. Similar results were observed in all of the examined
cell lines (N ¼ 4). We then assessed the protein production levels of
CCL3 by ELISA. We found signiﬁcant differences between responses
in both the salmeterol (P < 0.05) and the formoterol (P < 0.05)
groups by the KruskaleWallis test (Fig. 2c and d). Post hoc analyses
conﬁrmed signiﬁcant suppression of protein levels with concurrent
exposure of the cells to dexamethasone and salmeterol (P < 0.05)
(Fig. 2c) or formoterol (P < 0.05) (Fig. 2d). Similar results were
observed in all of the examined cell lines (N ¼ 4).
Airway epithelial cells are the ﬁrst to be impacted by inhaled
environmental factors and function in host defense and airway
inﬂammation.10 These cells act as an immunoregulator by produc-
ing various inﬂammatory mediators, and some of these mediators
induced by respiratory viral infections are considered to contribute
to exacerbations of chronic airway inﬂammatory diseases.3,10 CCL3
is increased in both the upper and the lower respiratory secretions
during viral infections, and bronchial epithelial cells produce CCL3
in the lower respiratory tract.6 In this study, we found a marked in-
crease in mRNA and secreted protein levels of CCL3 in Poly(I:C)
stimulated HNEpC. Thus, nasal epithelial cells might be a source
of CCL3 during viral infections of the upper respiratory tract.
Combinations of an ICS and LABA are widely used in anti-
inﬂammatory therapy and reduce acute exacerbations of asthma
and COPD. The combination therapy is more effective than ICS
monotherapy, and the airway epithelium is a major target for the
actions of inhaledmedications.10 ICS and LABA combinations syner-
gistically suppress proinﬂammatorymolecules produced by human
rhinovirus-infected or Poly(I:C)-stimulated bronchial epithelial
cells.4,5,10 In this study, we observed that HNEpC expressed asevier B.V. All rights reserved.
Fig. 1. CCL3 production by Poly(I:C) stimulated HNEpC and the presence of functional ADRB2 on HNEpC. a, b) HNEpC were stimulated with Poly(I:C) (1 mg/mL) for 24 h a) The CCL3
mRNA expression level was measured by quantitative RT-PCR. Data are shown as the mean of triplicate samples and are representative of four separate experiments. b) The con-
centration of CCL3 protein in the supernatant was measured using ELISA. Data are shown as the mean ± SD of triplicate samples and are representative of four separate experiments.
A dagger (y) indicates that the concentration was below the detection threshold (<7.81 pg/mL). c) The ADRB2 mRNA expression levels of unstimulated resting NHBE and HNEpC.
Data are shown as the mean ± SD of NHBE (N ¼ 16) and HNEpC (N ¼ 12). d, e) HNEpC were treated with ICI 118,551 (5 mM), and 30 min later, salmeterol (SAL) (0.1 mM) or formoterol
(FRM) (0.1 mM) was added. Intracellular cAMP was measured by ELISA 10 min after stimulation with salmeterol d) or formoterol e). Data are shown as the mean ± SD of quadru-
plicate samples and are representative of three separate experiments. *P < 0.01 by Welch's t-test.
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Fig. 2. Suppressive effects of long-acting beta agonists and dexamethasone on CCL3 production by Poly(I:C) stimulated HNEpC. HNEpC were treated with salmeterol (0.1 mM), for-
moterol (0.1 mM) and/or dexamethasone (1 mM), and the cells were stimulated with Poly(I:C) (1 mg/mL) for 24 h. The CCL3mRNA expression levels of cells treated with salmeterol a),
formoterol b) and/or dexamethasone were measured by real-time RT-PCR. Data are shown as the mean of triplicate samples and are representative of four separate experiments.
The concentrations of CCL3 protein in the supernatant treated with salmeterol c), formoterol d) and/or dexamethasone were measured using ELISA. Data are shown as the
mean ± SD of triplicate samples and are representative of four separate experiments. *P < 0.05 compared with Poly(I:C) stimulation by Scheffe's test.
Letter to the Editor / Allergology International 64 (2015) 196e199198much ADRB2 mRNA as NHBE, and the intracellular cAMP level was
increased in HNEpC by salmeterol or formoterol stimulation. We
also found that the combination of dexamethasone and a LABA
had a synergistic suppressive effect on CCL3 induction in HNEpC.
Corticosteroid nasal sprays are commonly used to treat allergic
rhinitis; however, b2 agonists are not used as theprincipalmedication
option for rhinitis. Acute exacerbationof chronic airway inﬂammation
is mostly started by upper airway viral infections.1,2 Although further
studies are needed, exhalation of the therapeutic agents through the
nosemighthelp to reduceCCL3 inductionand lessen theburdenof ex-
acerbations in patients receiving combination therapy.Acknowledgments
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